**Strong investor demand for Attovia Therapeutics' upsized IPO, priced at the top of the range on August 4, 2026, at $17 per share for 17 million shares, is the primary driver of current trader sentiment.** This generated $289 million in expected gross proceeds and an initial market capitalization of approximately $731–767 million on a fully diluted basis, reflecting favorable positioning for immune-mediated disease assets using the ATTOBODY platform. Biotech IPOs frequently experience first-day trading gains amid sector momentum, supporting elevated implied probabilities for outcomes above $900 million as real-money traders price in potential debut volatility. With shares set to begin Nasdaq trading under ATTO on August 5 and close anticipated August 6, subject to standard conditions, the market aggregates capital-backed views on post-pricing performance relative to comparable clinical-stage offerings.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado<$600M 37%
$700M-$800M 26%
$900M-$1B 24%
$600M-$700M 21%
NUEVO
NUEVO
5 ago 2026
<$600M
37%
$600M-$700M
21%
$700M-$800M
26%
$800M-$900M
21%
$900M-$1B
24%
$1 mil millones+
45%
No saldrá a bolsa antes de octubre de 2026
10%
<$600M 37%
$700M-$800M 26%
$900M-$1B 24%
$600M-$700M 21%
NUEVO
NUEVO
5 ago 2026
<$600M
$3 Vol.
37%
$600M-$700M
$0 Vol.
21%
$700M-$800M
$0 Vol.
26%
$800M-$900M
$0 Vol.
21%
$900M-$1B
$0 Vol.
24%
$1 mil millones+
$144 Vol.
45%
No saldrá a bolsa antes de octubre de 2026
$10 Vol.
10%
This market will resolve based on Attovia Therapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 5 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.**Strong investor demand for Attovia Therapeutics' upsized IPO, priced at the top of the range on August 4, 2026, at $17 per share for 17 million shares, is the primary driver of current trader sentiment.** This generated $289 million in expected gross proceeds and an initial market capitalization of approximately $731–767 million on a fully diluted basis, reflecting favorable positioning for immune-mediated disease assets using the ATTOBODY platform. Biotech IPOs frequently experience first-day trading gains amid sector momentum, supporting elevated implied probabilities for outcomes above $900 million as real-money traders price in potential debut volatility. With shares set to begin Nasdaq trading under ATTO on August 5 and close anticipated August 6, subject to standard conditions, the market aggregates capital-backed views on post-pricing performance relative to comparable clinical-stage offerings.
This market will resolve based on Attovia Therapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 5 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on August 5 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Mercado abierto: Aug 4, 2026, 9:51 PM ET
Volumen
$157Fecha de finalización
5 ago 2026Mercado abierto
Aug 4, 2026, 9:51 PM ETResolver
0x69c47De9D...This market will resolve based on Attovia Therapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 5 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.**Strong investor demand for Attovia Therapeutics' upsized IPO, priced at the top of the range on August 4, 2026, at $17 per share for 17 million shares, is the primary driver of current trader sentiment.** This generated $289 million in expected gross proceeds and an initial market capitalization of approximately $731–767 million on a fully diluted basis, reflecting favorable positioning for immune-mediated disease assets using the ATTOBODY platform. Biotech IPOs frequently experience first-day trading gains amid sector momentum, supporting elevated implied probabilities for outcomes above $900 million as real-money traders price in potential debut volatility. With shares set to begin Nasdaq trading under ATTO on August 5 and close anticipated August 6, subject to standard conditions, the market aggregates capital-backed views on post-pricing performance relative to comparable clinical-stage offerings.
This market will resolve based on Attovia Therapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 5 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on August 5 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Volumen
$157Fecha de finalización
5 ago 2026Mercado abierto
Aug 4, 2026, 9:51 PM ETResolver
0x69c47De9D...**Strong investor demand for Attovia Therapeutics' upsized IPO, priced at the top of the range on August 4, 2026, at $17 per share for 17 million shares, is the primary driver of current trader sentiment.** This generated $289 million in expected gross proceeds and an initial market capitalization of approximately $731–767 million on a fully diluted basis, reflecting favorable positioning for immune-mediated disease assets using the ATTOBODY platform. Biotech IPOs frequently experience first-day trading gains amid sector momentum, supporting elevated implied probabilities for outcomes above $900 million as real-money traders price in potential debut volatility. With shares set to begin Nasdaq trading under ATTO on August 5 and close anticipated August 6, subject to standard conditions, the market aggregates capital-backed views on post-pricing performance relative to comparable clinical-stage offerings.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado
Cuidado con los enlaces externos.
Cuidado con los enlaces externos.
Preguntas frecuentes